2024 Updates on Interstitial Lung Disease Clinical Trials

Recent Breakthroughs in Interstitial Lung Disease Pipeline

• March 2024: Boehringer Ingelheim announced a Double-Blind, Randomized, Placebo-Controlled Trial assessing the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
• April 2024: Boehringer Ingelheim launched a Prospective, Observational Study (the "INTENSE" Study) to explore correlations between changes in lung function and symptoms such as cough and dyspnea in patients with Connective Tissue Disease-associated Progressive Fibrosing Interstitial Lung Disease (CTD Associated PF-ILD), treated with Nintedanib.
• January 2024: aTyr Pharma, Inc. initiated a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept (PoC) Study to evaluate the efficacy, safety, and tolerability of Efzofitimod in patients with Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).

"Request a sample report for detailed insights into the Interstitial Lung Disease Pipeline Analysis ."

According to DataM Intelligence, the global Interstitial Lung Disease pipeline features over 145 key companies developing 130+ treatment therapies.

Key Takeaways from the Interstitial Lung Disease Pipeline Report:

• Major players in the treatment market include AdAlta, Bristol-Myers Squibb, aTyr Pharma , Avalyn Pharma , Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, Inc. , FibroGen, Inc. , PureTech Health, and Boehringer Ingelheim, among others.
• Emerging therapies such as AD-214, Abatacept, ATYR1923, Pirfenidone Inhalation, Lung Stem Cells, Bardoxolone Methyl, and Pamrevlumab are expected to significantly impact the market in the coming years.

"Interstitial Lung Disease Pipeline Insight, 2024" Report Overview:

The report offers a detailed analysis of pipeline products across various development stages, from pre-clinical to marketed phases. It covers key aspects such as the drug mechanism of action, clinical studies, NDA approvals, collaborations, mergers, and funding activities related to the drugs in development.

Interstitial Lung Disease Overview:

Interstitial lung disease (ILD) encompasses a wide range of disorders characterized by lung tissue inflammation and scarring, leading to impaired gas exchange. Symptoms typically include progressive shortness of breath, coughing, and fatigue. ILD can be caused by environmental exposures, autoimmune diseases, medications, or genetic predisposition. Diagnosis involves clinical evaluation, imaging (e.g., high-resolution CT scans), pulmonary function tests, and sometimes lung biopsies. Treatments aim to alleviate symptoms, slow progression, and improve quality of life, often through medications like corticosteroids, immunosuppressants, or antifibrotic agents. In severe cases, lung transplantation may be considered.

For more information, request a Free Sample PDF Report on the Interstitial Lung Disease Pipeline and Therapeutic Assessment.

Key Areas of Analysis in the Report:

• Route of Administration (ROA): Oral, Intravenous, and Subcutaneous routes are assessed for each drug.
• Molecule Type: Therapies are categorized into Small Molecules, Cell Therapy, Peptides, Polymer, and Gene Therapy.

Download the full report to explore the emerging Interstitial Lung Disease therapies and drugs, including detailed analysis of the development stages, collaborations, and financing details that drive market advancements.

Scope of the Interstitial Lung Disease Pipeline Drug Insight:

• Coverage: Global
• Companies: Key players such as AdAlta Ltd , Bristol Myers Squibb , Boehringer Ingelheim , and PureTech Health are highlighted.
• Key Therapies: Emerging treatments include AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, Lung Stem Cells, and Bardoxolone methyl.